Amicus Therapeutics’ (FOLD) Outperform Rating Reiterated at Robert W. Baird
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reissued by stock analysts at Robert W. Baird in a research report issued to clients and investors on Wednesday. They presently have a $18.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $16.00. Robert W. Baird’s price target would suggest a potential upside of 10.84% from the company’s previous close.
Other equities analysts have also issued research reports about the company. Leerink Swann reissued an “outperform” rating and set a $20.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $15.00 target price (up from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research note on Monday, August 14th. Chardan Capital lifted their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Amicus Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.92.
Shares of Amicus Therapeutics (FOLD) traded up 9.21% during mid-day trading on Wednesday, hitting $16.24. 10,582,440 shares of the stock traded hands. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $16.60. The firm has a 50 day moving average of $13.82 and a 200 day moving average of $10.45. The company’s market cap is $2.67 billion.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period in the previous year, the firm posted ($0.40) EPS. Equities analysts anticipate that Amicus Therapeutics will post ($1.31) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/amicus-therapeutics-fold-outperform-rating-reiterated-at-robert-w-baird/1608504.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of Amicus Therapeutics stock in a transaction on Thursday, July 13th. The shares were bought at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.40% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its position in shares of Amicus Therapeutics by 11.5% during the 1st quarter. Nationwide Fund Advisors now owns 131,945 shares of the biopharmaceutical company’s stock worth $941,000 after purchasing an additional 13,563 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Amicus Therapeutics by 1,004.9% in the 1st quarter. Russell Investments Group Ltd. now owns 121,338 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 110,356 shares during the period. Wells Fargo & Company MN raised its holdings in Amicus Therapeutics by 51.7% in the 1st quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock valued at $1,094,000 after buying an additional 52,287 shares during the period. Bank of New York Mellon Corp raised its holdings in Amicus Therapeutics by 12.5% in the 1st quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 74,700 shares during the period. Finally, UBS Asset Management Americas Inc. raised its holdings in Amicus Therapeutics by 71.8% in the 1st quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 21,174 shares during the period.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.